1.中山大学药学院药理与毒理教研室,广东 广州 510006
2.广州中医药大学中药学院,广东 广州 510006
3.中山大学医学院药理教研室,广东 深圳 518107
陈秋荷,硕士,E-mail:chenqh25@mail2.sysu.edu.cn
收稿:2021-05-20,
纸质出版:2021-09-20
移动端阅览
陈秋荷,涂亚林,侯加卫等.PT109改善链脲佐菌素诱导的散发性阿尔茨海默病小鼠认知功能障碍的作用及机制[J].中山大学学报(医学科学版),2021,42(05):694-702.
CHEN Qiu-he,TU Ya-lin,HOU Jia-wei,et al.PT109 Ameliorates Cognitive Impairment in the Streptozotocin-induced Sporadic Alzheimer’S Disease Mice and Its Mechanisms[J].Journal of Sun Yat-sen University(Medical Sciences),2021,42(05):694-702.
陈秋荷,涂亚林,侯加卫等.PT109改善链脲佐菌素诱导的散发性阿尔茨海默病小鼠认知功能障碍的作用及机制[J].中山大学学报(医学科学版),2021,42(05):694-702. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0507.
CHEN Qiu-he,TU Ya-lin,HOU Jia-wei,et al.PT109 Ameliorates Cognitive Impairment in the Streptozotocin-induced Sporadic Alzheimer’S Disease Mice and Its Mechanisms[J].Journal of Sun Yat-sen University(Medical Sciences),2021,42(05):694-702. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0507.
目的
2
观察PT109能否改善侧脑室注射链脲佐菌素(icv-STZ)诱导的散发性AD小鼠模型的认知功能障碍并对其机制进行初步探讨。
方法
2
32只7周龄雄性C57BL/6小鼠分为正常组(7只)、模型组(7只)、PT109低剂量组(9只)、PT109高剂量组(9只)。将STZ于第1和3天注射入小鼠侧脑室建立散发性阿尔茨海默病小鼠模型;(3mg/kg,每个注射位点5μL)造模后,分别腹腔注射PT109(30、100 mg·kg
-1
·d
-1
),2周后通过Morris水迷宫和避暗实验评价小鼠学习记忆能力;随后通过免疫荧光、免疫组化、免疫印迹、高尔基染色等方法检测小胶质细胞、神经元、树突棘、磷酸化Tau蛋白等AD相关指标。
结果
2
行为学实验结果显示:PT109可改善icv-STZ小鼠的学习记忆障碍;免疫荧光及组化结果显示:与模型组相比,PT109减少海马区域Iba1阳性细胞数量(低剂量:
P
<
0.001, 高剂量:
P
<
0.001),高剂量PT109增加海马和皮层区域MAP2和Tuj1阳性细胞总数量(
P
<
0.05,
P
<
0.01),差异具有统计学意义。高尔基染色结果显示:与模型组相比,PT109增加树突棘密度(低剂量:
P
<
0.001, 高剂量:
P
<
0.001),差异具有统计学意义。免疫印迹实验结果表明:与模型组相比,PT109降低NLRP3(高剂量:
P
<
0.05)、磷酸化Tau蛋白的表达水平(低剂量:
P
<
0.05, 高剂量:
P
<
0.01),高剂量PT109提高PSD95(
P
<
0.05)、磷酸化GSK3β(
P
<
0.05)的表达水平,差异具有统计学差异。
结论
2
PT109可改善icv-STZ诱导的小鼠学习记忆障碍,可能与调节GSK3β/Tau相关通路有关。
Objective
2
To observe whether PT109 [5-(1,2-dithiolan-3-yl)-N-(4-(isoquinolin-5-ylamino)cyclohexyl)pentanamide] could improve the cognitive dysfunction in sporadic AD mice induced by lateral ventricular injection of streptozotocin and study the underlying mechanisms.
Methods
2
Thirty-two seven-week-old male C57BL/6 mice were randomly divided into 4 groups: control group (7 mice), model group (7 mice), PT109 low dosage group (9 mice) and PT109 high dosage group (9 mice). To establish the sporadic Alzheimer’s disease, these mice were injected with intracerebroventricular streptozotocin on the first and third day (3 mg/kg, 5 μL per injection site). Then PT109 (30, 100 mg·kg
-1
·d
-1
) was injected intraperitoneally. Two weeks later, Morris water maze and step through test were used to evaluate the effect of PT109 on the learning and memory ability of AD mice. The AD related indexes such as microglia, neurons, dendritic spines and phosphorylated Tau protein were detected by immunofluorescence, immunohistochemistry, western blotting and Golgi staining.
Results
2
The behavioral experiments results showed that PT109 could improve the learning and memory impairment. The immunofluorescence and immunohistochemistry staining results showed that compared with model group, PT109 reduced the number of Iba1 positive cell in hippocampus region (low dosage:
P
<
0.001, high dosage:
P
<
0.001) and high dosage PT109 increased the total number of MAP2 and Tuj1 positive cell in hippocampus and cortex region (
P
<
0.05,
P
<
0.01). The Golgi staining results showed that compared with model group, PT109 increased the density of dendritic spines (low dosage:
P
<
0.001, high dosage:
P
<
0.001). The western blotting results showed that compared with model group, PT109 decreased the protein levels of NLRP3 (high dosage:
P
<
0.05 ) and phosphorylated Tau protein (low dosage:
P
<
0.05, high dosage:
P
<
0.01 ), and high dosage PT109 increased the protein levels of PSD95 (
P
<
0.05) and phosphorylated GSK3β (
P
<
0.05).
Conclusion
2
PT109 could improve the learning and memory impairment of icv-STZ mice, which might be related to the regulation of GSK3β/Tau pathway.
2020 Alzheimer's disease facts and figures [J]. Alzheimers Dement , 2020 , 16 ( 3 ): 1 - 70 .
Rochais C , Lecoutey C , Gaven F , et al . Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride [J]. J Med Chem , 2015 , 58 ( 7 ): 3172 - 3187 .
Masters CL , Bateman R , Blennow K , et al . Alzheimer's disease [J]. Nat Rev Dis Primers , 2015 , 2015( 15056 ): 1 - 18 .
Pinton S , da Rocha JT , Gai BM , et al . Sporadic dementia of Alzheimer's type induced by streptozotocin promotes anxiogenic behavior in mice [J]. Behav Brain Res , 2011 , 223 ( 1 ): 1 - 6 .
Soni ND , Ramesh A , Roy D , et al . Brain energy metabolism in intracerebroventricularly administered streptozotocin mouse model of Alzheimer's disease: A (1)H-[(13)C]-NMR study [J]. J Cereb Blood Flow Metab , 2021 , doi: 10.1177/0271678X21996176 http://dx.doi.org/10.1177/0271678X21996176 .
Knezovic A , Osmanovic-Barilar J , Curlin M , et al . Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease [J]. J Neural Transm , 2015 , 122 ( 4 ): 577 - 592 .
Chen YX , Liang ZH , Blanchard J , et al . A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse) [J]. Mol Neurobiol , 2013 , 47 ( 2 ): 711 - 725 .
Kamat PK , Kalani A , Rai S , et al . Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: a therapeutic intervention for treatment of sporadic Alzheimer's disease (sAD)-like pathology [J]. Mol Neurobiol , 2016 , 53 ( 7 ): 4548 - 4562 .
Chen QH , Tu YL , Mak SH , et al . Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer’s disease in vitro and in vivo [J]. Eur J Pharmacol , 2020 , 883 : 1 - 14 .
Lu YJ , Dong Y , Tucker D , et al . Treadmill exercise exerts neuroprotection and regulates microglial polarization and oxidative stress in a streptozotocin-induced rat model of sporadic Alzheimer's disease [J]. J Alzheimers Dis , 2017 , 56 ( 4 ): 1469 - 1484 .
Katsumoto A , Takeuchi H , Takahashi K , et al . Microglia in Alzheimer's disease: risk factors and inflammation [J]. Front Neurol , 2018 , 9 : 978 .
Wei PH , Yang F , Zheng Q , et al . The potential role of the NLRP3 inflammasome activation as a link between mitochondria ROS generation and neuroinflammation in postoperative cognitive dysfunction [J]. Front Cell Neurosci , 2019 , 13 : 73 .
Wirths O , Zampar S . Neuron loss in Alzheimer's disease: translation in transgenic mouse models [J]. Int J Mol Sic , 2020 , 21 ( 21 ): 1 - 19 .
Guzman-Ramos K , Moreno-Castilla P , Castro-Cruz M , et al . Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease [J]. Learn Memory , 2012 , 19 ( 10 ): 453 - 460 .
Gao WL , Li XH , Dun XP , et al . Grape seed proanthocyanidin extract ameliorates streptozotocin-induced cognitive and synaptic plasticity deficits by inhibiting oxidative stress and preserving AKT and ERK activities [J]. Curr Med Sic , 2020 , 40 ( 3 ): 434 - 443 .
Martin L , Latypova X , Wilson CM , et al . Tau protein kinases: involvement in Alzheimer's disease [J]. Ageing Res Rev , 2013 , 12 ( 1 ): 289 - 309 .
West S , Bhugra P . Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review [J]. Br J Clin Pharmacol , 2015 , 80 ( 2 ): 221 - 234 .
Toral-Rios D , Pichardo-Rojas PS , Alonso-Vanegas M , et al . GSK3beta and tau protein in Alzheimer's disease and epilepsy [J]. Front Cell Neurosci , 2020 , 14 : 1 - 9 .
Lauretti E , Dincer O , Praticò D . Glycogen synthase kinase-3 signaling in Alzheimer's disease [J]. Biochim Biophys Acta Mol Cell Res , 2020 , 1867 ( 5 ): 1 - 17 .
0
浏览量
257
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
